Shots:

• Blueprint Medicine to receive $675M as up front- $100M as an equity investment and is eligible to receive up to $927M as development- regulatory and commercial milestones along with royalties on sales of therapy outside the US
• Roche to get an exclusive right to co-develop globally and commercialize pralsetinib outside the US- excluding Greater China. In the US- Roche will get co-commercialization rights to pralsetinib. The companies will share global development expenses based on pre-specified cost-sharing percentages and equally share profits and losses in the US
• Pralsetinib (qd- PO) is precision therapy for the treatment of patients with RET-altered NSCLC- MTC and other types of thyroid cancer- and solid tumors and has demonstrated tumor-agnostic potential with its PDUFA date as Nov 23- 2020

Click here to read full press release/ article 

Ref: Roche | Image: Roche